Neumora Therapeutics, Inc. · NASDAQ:NMRA
Neumora Therapeutics — J.P. Morgan Healthcare Conference January 2024
28 slides from Neumora Therapeutics's conference presentation, Jan 8, 2024
Slide 1: J.P. Morgan Healthcare Conference January 2024
Exhibit 99.1 J.P. Morgan Healthcare Conference January 2024
Slide 2: Important Disclosures
Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by brin
Slide 3: Our Mission
Our Mission We are focused on redefining neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases 3 3
Slide 4: We Have Built A Leading Neuroscience Company
We Have Built A Leading Neuroscience Company • $650M in private capital raised, including $100M+ each from ARCH and Amgen • Assembled pipeline of 7 novel CNS programs supported by long-dated composition of matter patents, into 2041+ 2019 – 2022 Built at Scale • Led by experienced company builders an
Slide 5: Tackling One of the Largest Population Health Markets with Potential for Significant Patient Impact
Tackling One of the Largest Population Health Markets with Potential for Significant Patient Impact Starting in 2026 Neumora has potential to address up to ~40M+ patients starting in 2026 with a robust IP runway into 2041+ 1 Biggest Health Disorders Facing U.S. Patients Impacted (M) ~40M+ Patient Op
Slide 6: Advancing a Leading Neuroscience Pipeline
Advancing a Leading Neuroscience Pipeline PROGRAM INDICATION • Broad pipeline addressing Target/Mechanism U.S. Prevalence Preclinical Phase 1 Phase 2 Phase 3 some of the most prevalent brain Neuropsychiatry Programs health disorders Major Depressive Disorder 21M Navacaprant (NMRA-140) • Targeting no
Slide 7: Clinical Stage Neuropsychiatry Portfolio Pursuing Large Markets with Clinically Validated Targets
Clinical Stage Neuropsychiatry Portfolio Pursuing Large Markets with Clinically Validated Targets Differentiated programs with broad potential Navacaprant NMRA-266 NMRA-511 M4 Receptor Positive Allosteric Mechanism Kappa Opioid Receptor Antagonist V1a Receptor Antagonist Modulator Stage Phase 3 Phas
Slide 8: Advancing an Exciting Set of Preclinical Programs
Advancing an Exciting Set of Preclinical Programs Strong biological rationale NMRA-CK1δ NMRA-NLRP3 NMRA-GCase NMRA-NMDA NMDA Positive Allosteric Mechanism CK1δ Inhibitor NLRP3 Inhibitor GCase Activator Modulator Potential Indications ALS, Alzheimer’s Disease Parkinson’s Disease Parkinson’s Disease S
Slide 9: Navacaprant is the Best-in-Class Kappa Opioid Receptor Antagonist
Navacaprant is the Best-in-Class Kappa Opioid Receptor Antagonist with a Differentiated Clinical Profile Expected Upcoming Program Milestones Navacaprant Profile • Selective KOR antagonist with >300-fold selectivity for KOR over MOR and 90% receptor 2024 1,2 occupancy coverage • Topline data from KO
Slide 10: Navacaprant Pharmacology Differentiated from Other Kappa Opioid Receptor Antagonists
Navacaprant Pharmacology Differentiated from Other Kappa Opioid Receptor Antagonists in Clinical Development 1,2 3,4 5,6 Navacaprant Aticaprant CVL-354 Binding Selectivity ~310x selectivity ~30x selectivity 31x selectivity (Ki nM) for KOR over MOR for KOR over MOR for KOR over MOR KOR Receptor 95-87
Slide 11: First Program to Demonstrate Efficacy in Symptoms of Depression and Anhedonia
First Program to Demonstrate Efficacy in Symptoms of Depression and Anhedonia HAMD-17 Week 0 Week 4 Week 8 Safety profile with significant advantages 0 over existing treatment options Robust Phase 2 Data -2 • Study included 40 sites in the U.S. -4 TEAEs Incidence (≥2% in either treatment group) • 20
Slide 12: Near-term Clinical Development Plan Focused on MDD with Opportunity for Further Expansion
Near-term Clinical Development Plan Focused on MDD with Opportunity for Further Expansion Navacaprant Clinical Development Programs Major Depressive Disorder Additional Bipolar Depression Neuropsych Opportunities Substance KOASTAL-LT Phase 2 Three replicate, placebo-controlled, double-blind RCTs eva
Slide 13: KOASTAL Pivotal Study Design Well Suited for Navacaprant Pharmacology
������������ ���� �� KOASTAL Pivotal Study Design Well Suited for Navacaprant Pharmacology KOASTAL Pivotal Efficacy Studies Robust placebo Navacaprant 80 mg QD Opportunity minimization R to enroll in strategies include 1:1 KOASTAL-LT stringent site Placebo QD selection, substantial internal medical
Slide 14: Navacaprant Would Enter Large MDD Market with a Highly Differentiated Profile
Navacaprant Would Enter Large MDD Market with a Highly Differentiated Profile Growth in addressable MDD market expected in-line with Prescribers prefer navacaprant compared to approved agents population growth; majority of patients treated with due to novel mechanism, superior dosing and side effect
Slide 15: NMRA-266 is a Potentially Differentiated M4 Receptor PAM for Schizophrenia
NMRA-266 is a Potentially Differentiated M4 Receptor PAM for Schizophrenia 2 3 NMRA-266 Emraclidine Pharmacology Designed as a highly selective M4 muscarinic M EC (cAMP) 32 nM 12 nM 4 50 receptor PAM for antipsychotic-like efficacy with the potential for improved safety profile Human t Pending Phase
Slide 16: NMRA-511 is a Best-in-Class V1aR Antagonist
NMRA-511 is a Best-in-Class V1aR Antagonist with Broad Potential Across Neuropsychiatric Disorders 1 NMRA-511 Pharmacology • Antagonist of vasopressin 1a receptor (V1aR), with high selectivity Potency 0.9 nM over V1b, V2 (greater than 3,000-fold) and oxytocin receptors (functional IC50) (approximate
Slide 17: 2024 and 2025 Are Catalyst Rich Years for Neumora
2024 and 2025 Are Catalyst Rich Years for Neumora Built at Scale Leading Pipeline Innovative Approach Raised >$850M to date from leading investors with a team of Advancing seven NCE therapeutic candidates with novel MOAs Maximizing the value of our programs to potentially increase the expert company
Slide 18: Building a leading neuroscience company
Building a leading neuroscience company Opportunity to reach 100M+ patients with novel, best-in- class pharmacology Two clinically de-risked programs advancing rapidly Strong pre-clinical pipeline enabling steady IND flow Novel chemistry enabled composition of matter patents for each program into 20
Slide 19: Appendix
Appendix 19
Slide 20: Led by Experienced Company Builders and Leading Neuroscience Drug Developers
Led by Experienced Company Builders and Leading Neuroscience Drug Developers Leadership Board of Directors Paul L. Berns Henry Gosebruch Carol Suh Paul L. Berns Co-Founder and Executive Chairman Chief Executive Officer Chief Operating Officer and Co-Founder Co-Founder, Executive Chair Henry Gosebruc
Slide 21: Navacaprant: Demonstrated Efficacy Across Broad Range of Treatment Outcome Measures
Navacaprant: Demonstrated Efficacy Across Broad Range of Treatment Outcome Measures in Moderate-to-Severe Population Week 4 Difference Week 8 Difference (p-value) (p-value) Depressive Symptom Improvement -3.0 -2.8 HAMD-17 Total Score Change from Baseline (0.015) (0.037) 21.4% 25.9% HAMD-17 Response
Slide 22: Navacaprant: MDD Market in U.S. Provides Potential Large Blockbuster Opportunity
Navacaprant: MDD Market in U.S. Provides Potential Large Blockbuster Opportunity for Differentiated Product with Novel Mechanism of Action MDD Market Represents Large Patient Opportunity Neuropsychology Pricing Catalogues GTN WAC 21M Patients Diagnosed in U.S. (per month) discount 50% not on therapy
Slide 23: Strong Rationale for Efficacy in Bipolar Depression
Strong Rationale for Efficacy in Bipolar Depression Navacaprant in Bipolar Depression (BPD): • Evidence from the navacaprant Phase 2 and NIMH’s FASTMAS demonstrate utility of KOR pharmacology for depression and 1 anhedonia • Anhedonia is a highly prevalent and clinically relevant symptom in BPD • A
Slide 24: Schizophrenia Market Supports Multiple Treatment Options
Schizophrenia Market Supports Multiple Treatment Options Historically the schizophrenia market has supported multiple branded products with similar MOAs, with new entrants driving higher overall market sales volume Sales of Branded 5-HT2 to D2 Receptor Antagonists (1995 – 2013) 12,000 Product Launch
Slide 25: NMRA-511 Reduces Threat Behaviors in Marmosets and Alters EEG Power Spectra
NMRA-511 Reduces Threat Behaviors in Marmosets and Alters EEG Power Spectra Similarly in Marmosets and Humans In a human threat test (HTT) study completed in marmosets, NMRA-511 demonstrated activity in brain circuits that regulate mood and anxiety. An additional EEG study demonstrated that the phar
Slide 26: Advancing Four Novel Pre-Clinical Programs, Each with A Strong Biological Rationale
Advancing Four Novel Pre-Clinical Programs, Each with A Strong Biological Rationale NMRA-CK1δ NMRA-NMDA NMRA-NLRP3 NMRA-GCASE Focused on inhibiting the protein casein NMDA receptor hypofunction is a Focused on inhibiting the NLRP3 Focused on elevating activity of the kinase-1δ (CK1δ) to reduce level
Slide 27: Neumora's Precision Medicine Approach Can Be Leveraged to Maximize the Value of Our Programs
Neumora’s Precision Medicine Approach Can Be Leveraged to Maximize the Value of Our Programs Challenge: Match Right Neumora’s Maximize Value: Improve Drug to the Right Patient Precision Toolbox Probability of Success & Proprietary analytical capabilities with Expand Indications one petabyte of data
Slide 28: Neumora
Y) Neumora
Neumora Therapeutics — J.P. Morgan Healthcare Conference January 2024 on 6ix